Zimmer Biomet Holdings Hits New 52-Week Low at $81.36

Zimmer Biomet Holdings, Inc. has reached a new 52-week low, trading at USD 81.36 as of April 28, 2026. This marks a significant decline for the mid-cap company, which operates within the Pharmaceuticals & Biotechnology sector. Over the past year, Zimmer Biomet has experienced a notable drop of 26.65%, contrasting sharply with the S&P 500's performance of 29.12%. The company's financial metrics reveal a P/E ratio of 30.00 and a dividend yield of 18.46%. However, its return on equity stands at 7.46%, indicating challenges in generating profits relative to shareholder equity. The debt-to-equity ratio is reported at 0.55, suggesting a moderate level of leverage. Despite its market capitalization of USD 27,939 million, Zimmer Biomet has struggled with long-term growth, evidenced by a net sales growth rate of only 2.19% and an operating profit growth of 14.17% over the past five years. The stock's performance has consistently lagged behind the S&P 500, reflecting ongoing difficulties in achieving positive returns for shareholders.